22.67
price up icon0.58%   0.13
after-market Handel nachbörslich: 22.67
loading
Schlusskurs vom Vortag:
$22.54
Offen:
$22.54
24-Stunden-Volumen:
96,129
Relative Volume:
1.16
Marktkapitalisierung:
$289.99M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+2.77%
1M Leistung:
-6.05%
6M Leistung:
+88.92%
1J Leistung:
+0.00%
1-Tages-Spanne:
Value
$21.55
$23.14
1-Wochen-Bereich:
Value
$20.35
$23.69
52-Wochen-Spanne:
Value
$11.17
$29.27

Palvella Therapeutics Inc Stock (PVLA) Company Profile

Name
Firmenname
Palvella Therapeutics Inc
Name
Telefon
(484) 253-1461
Name
Adresse
125 STRAFFORD AVE, WAYNE
Name
Mitarbeiter
14
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
PVLA's Discussions on Twitter

Vergleichen Sie PVLA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
PVLA
Palvella Therapeutics Inc
22.67 289.99M 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.16 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
534.91 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.06 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.47 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.16 28.51B 3.81B -644.79M -669.77M -6.24

Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-09 Eingeleitet Chardan Capital Markets Buy
2025-03-26 Eingeleitet Stifel Buy
2025-03-07 Eingeleitet Scotiabank Sector Outperform
2025-02-20 Eingeleitet Canaccord Genuity Buy
2025-02-05 Eingeleitet TD Cowen Buy
2024-12-26 Eingeleitet H.C. Wainwright Buy
2024-12-18 Eingeleitet Cantor Fitzgerald Overweight
2020-03-13 Hochstufung Robert W. Baird Neutral → Outperform
2019-07-30 Herabstufung Robert W. Baird Outperform → Neutral
2019-05-14 Eingeleitet Robert W. Baird Outperform
2018-03-19 Eingeleitet Evercore ISI Outperform
2018-03-19 Eingeleitet Jefferies Buy
2018-01-16 Bestätigt H.C. Wainwright Buy
2017-05-30 Eingeleitet Rodman & Renshaw Buy
2016-08-05 Fortgesetzt ROTH Capital Buy
2015-08-12 Eingeleitet JMP Securities Mkt Outperform
2015-07-27 Eingeleitet Oppenheimer Outperform
2015-07-22 Eingeleitet ROTH Capital Buy
Alle ansehen

Palvella Therapeutics Inc Aktie (PVLA) Neueste Nachrichten

pulisher
Jun 18, 2025

Palvella Therapeutics Secures New Patent for QTORIN™ Rapamycin - MyChesCo

Jun 18, 2025
pulisher
Jun 18, 2025

Palvella Therapeutics Receives US Patent for Qtorin Topical Gel Candidate - MarketScreener

Jun 18, 2025
pulisher
Jun 18, 2025

Palvella Therapeutics Granted Sixth U.S. Patent Covering - GlobeNewswire

Jun 18, 2025
pulisher
Jun 18, 2025

Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1-20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors - The Manila Times

Jun 18, 2025
pulisher
Jun 18, 2025

Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of - Bluefield Daily Telegraph

Jun 18, 2025
pulisher
Jun 18, 2025

Palvella's Game-Changing QTORIN Patent Locks in 15+ Years of Market Protection for Rare Disease Treatment - Stock Titan

Jun 18, 2025
pulisher
Jun 12, 2025

Palvella Therapeutics Secures FDA Grant Funding for Phase 3 Trial of QTORIN Rapamycin - MSN

Jun 12, 2025
pulisher
Jun 12, 2025

Cantor Fitzgerald Weighs in on PVLA FY2026 Earnings - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

Palvella Therapeutics Holds Annual Stockholders Meeting - TipRanks

Jun 11, 2025
pulisher
Jun 11, 2025

Palvella Therapeutics (NASDAQ:PVLA) Receives $46.29 Consensus Price Target from Analysts - Defense World

Jun 11, 2025
pulisher
Jun 09, 2025

Palvella Therapeutics receives FDA grant for rare disease trial By Investing.com - Investing.com South Africa

Jun 09, 2025
pulisher
Jun 09, 2025

Palvella Therapeutics Says Top-Line Data From SELVA Expected In Q1 2026 - marketscreener.com

Jun 09, 2025
pulisher
Jun 09, 2025

Palvella Therapeutics receives FDA grant for rare disease trial - Investing.com

Jun 09, 2025
pulisher
Jun 09, 2025

Palvella Therapeutics Receives Initial Proceeds from FDA - GlobeNewswire

Jun 09, 2025
pulisher
Jun 09, 2025

Citadel Advisors LLC Makes New Investment in Palvella Therapeutics (NASDAQ:PVLA) - Defense World

Jun 09, 2025
pulisher
Jun 01, 2025

Palvella Therapeutics Names Ashley Kline Chief Commercial Officer - MSN

Jun 01, 2025
pulisher
May 30, 2025

Palvella Therapeutics Advances in Rare Skin Disease Therapies - TipRanks

May 30, 2025
pulisher
May 30, 2025

A great week for institutional investors who own 26% of Palvella Therapeutics, Inc. (NASDAQ:PVLA) - simplywall.st

May 30, 2025
pulisher
May 28, 2025

Palvella Therapeutics Strengthens Executive Leadership Team - GlobeNewswire

May 28, 2025
pulisher
May 27, 2025

Palvella Therapeutics hires Ashley Kline as Chief Commercial Officer - Investing.com

May 27, 2025
pulisher
May 27, 2025

Palvella Therapeutics hires Ashley Kline as Chief Commercial Officer By Investing.com - Investing.com India

May 27, 2025
pulisher
May 27, 2025

Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer - The Manila Times

May 27, 2025
pulisher
May 27, 2025

Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease ... - Eagle-Tribune

May 27, 2025
pulisher
May 27, 2025

Palvella Taps Rare Disease Star Who Led $500M Oxervate Launch for Upcoming Genetic Disease Treatment - Stock Titan

May 27, 2025
pulisher
May 22, 2025

Brokers Set Expectations for PVLA FY2025 Earnings - Defense World

May 22, 2025
pulisher
May 19, 2025

Palvella Therapeutics Reports Q1 2025 Financials and Clinical Progress - MSN

May 19, 2025
pulisher
May 18, 2025

Canaccord Genuity Group Has Lowered Expectations for Palvella Therapeutics (NASDAQ:PVLA) Stock Price - Defense World

May 18, 2025
pulisher
May 18, 2025

Palvella Therapeutics to Announce Q1 2025 Financial Results and Host Investor Call - MSN

May 18, 2025
pulisher
May 17, 2025

Mineralys Therapeutics Announces Q1 2025 Financial Results and Achievements - MyChesCo

May 17, 2025
pulisher
May 17, 2025

Analysts Set Palvella Therapeutics (NASDAQ:PVLA) Price Target at $44.43 - Defense World

May 17, 2025
pulisher
May 16, 2025

Palvella Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat

May 16, 2025
pulisher
May 16, 2025

Palvella Therapeutics: Q1 Earnings Snapshot - CT Insider

May 16, 2025
pulisher
May 15, 2025

Earnings call transcript: Palvella Therapeutics reports Q1 2025 loss, stock dips - Investing.com Nigeria

May 15, 2025
pulisher
May 15, 2025

Palvella Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 15, 2025
pulisher
May 15, 2025

Palvella Therapeutics Reports Strong Q1 Financial Results - TipRanks

May 15, 2025
pulisher
May 15, 2025

PALVELLA THERAPEUTICS Earnings Results: $PVLA Reports Quarterly Earnings - Nasdaq

May 15, 2025
pulisher
May 15, 2025

PALVELLA THERAPEUTICS, INC. SEC 10-Q Report - TradingView

May 15, 2025
pulisher
May 15, 2025

Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times

May 15, 2025
pulisher
May 15, 2025

Palvella's Breakthrough Skin Disease Treatment Hits Major Milestone as Phase 3 Trial Surpasses Target - Stock Titan

May 15, 2025
pulisher
May 13, 2025

Palvella Therapeutics (PVLA) Projected to Post Quarterly Earnings on Thursday - Defense World

May 13, 2025
pulisher
May 12, 2025

Palvella Therapeutics Rings the Nasdaq Stock Market Opening Bell - Nasdaq

May 12, 2025
pulisher
May 12, 2025

Palvella Therapeutics Rings the Opening Bell - Nasdaq

May 12, 2025
pulisher
May 09, 2025

Palvella Therapeutics to Ring Nasdaq Opening Bell - MyChesCo

May 09, 2025
pulisher
May 08, 2025

Palvella Therapeutics to Host First Quarter 2025 Financial - GlobeNewswire

May 08, 2025

Finanzdaten der Palvella Therapeutics Inc-Aktie (PVLA)

Es liegen keine Finanzdaten für Palvella Therapeutics Inc (PVLA) vor. Überprüfen Sie andere Aktien für weitere Informationen.

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Palvella Therapeutics Inc-Aktie (PVLA) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
JENKINS GEORGE M
Director
Apr 09 '25
Buy
20.13
2,500
50,325
183,171
JENKINS GEORGE M
Director
Dec 18 '24
Buy
12.93
4,000
51,720
180,671
GERAGHTY JAMES A
Director
Aug 07 '24
Buy
1.00
1
1
1
ADAR1 Capital Management, LLC
10% Owner
Aug 12 '24
Buy
15.88
3,000
47,647
129,574
ADAR1 Capital Management, LLC
10% Owner
Aug 09 '24
Buy
14.89
3,000
44,679
127,331
$20.74
price up icon 0.39%
$35.88
price down icon 0.42%
$21.20
price down icon 0.38%
$97.62
price down icon 3.00%
$107.51
price up icon 0.98%
biotechnology ONC
$245.16
price up icon 1.28%
Kapitalisierung:     |  Volumen (24h):